消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

2021 CSCO临床指南：胃癌的诊断和治疗（英文版）

中国临床肿瘤学会 中国临床肿瘤学会

治疗胃癌诊断

本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。

中文标题：

2021 CSCO临床指南：胃癌的诊断和治疗（英文版）

英文标题：

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

发布机构：

中国临床肿瘤学会

发布日期：

简要介绍：

本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 CSCO临床指南：胃癌的诊断和治疗（英文版）.pdf)] GetToolGuiderByIdResponse(projectId=1, id=a97061c00212583c, title=2021 CSCO临床指南：胃癌的诊断和治疗（英文版）, enTitle=The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021, guiderFrom=中国临床肿瘤学会, authorId=0, author=, summary=本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。, cover=https://img.medsci.cn/202175/1625470678288_5433779.jpeg, journalId=0, articlesId=null, associationId=863, associationName=中国临床肿瘤学会, associationIntro=null, copyright=0, guiderPublishedTime=null, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。</span></p>, tagList=[TagDto(tagId=65, tagName=治疗), TagDto(tagId=438, tagName=胃癌), TagDto(tagId=757, tagName=诊断)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=76, categoryName=胃肠外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=438, articleKeyword=胃癌, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=15682, appHits=942, showAppHits=0, pcHits=2463, showPcHits=14736, likes=4, shares=74, comments=40, approvalStatus=1, publishedTime=Mon Jul 05 15:40:21 CST 2021, publishedTimeString=null, pcVisible=1, appVisible=1, editorId=5433779, editor=Oranhyg是正经人, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=Oranhyg是正经人, createdTime=Mon Jul 05 15:38:09 CST 2021, updatedBy=5433779, updatedName=Oranhyg是正经人, updatedTime=Sat Jan 06 17:44:46 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 CSCO临床指南：胃癌的诊断和治疗（英文版）.pdf)])
2021 CSCO临床指南：胃癌的诊断和治疗（英文版）.pdf
下载请点击：
评论区 (26)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2022-03-15 吴卓远108

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2022-02-25 ms4000001880486183

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-11-04 ms2000000908561621

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-23 ms6000000590698351

    有中文吗

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 147c0641m47暂无昵称

    学习了

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2017 嗜酸性筋膜炎的诊断标准，严重性分级和治疗指南

国外皮肤性病相关专家小组（统称） · 2017-12-13

2017 ASA立场声明：成人失眠症的心理/行为治疗

澳大拉西亚睡眠协会(ASA,Australasian Sleep Association) · 2017-06-20

2017 NAMS立场声明：激素治疗

北美绝经学会(NAMS,The North American Menopause Society) · 2017-06-24

解读2015年美国风湿病学会强直性脊柱炎和放射学阴性中轴型脊柱关节炎新的治疗推荐

暂未更新 · 2016-07-30

中国成人艰难梭菌感染诊断和治疗专家共识

暂未更新 · 2017-06-20

2016年中国超重/肥胖医学营养治疗专家共识解读

暂未更新 · 2017-05-30

拓展阅读

38%胃癌患者肿瘤近乎完全消失，缓解率翻2.6倍！北肿沈琳&彭智团队：有这三种特征的人更能获益

中国早期胃癌占比低，胃食管结合部癌治疗存挑战。研究表明，阿替利珠单抗联合方案较传统方案显著提高可手术局部晚期 HER2 阳性患者病理完全缓解率，安全性良好。

【衡道丨干货】2025 中国肿瘤整合诊治指南（CACA) ——胃癌

本文介绍胃癌病理概念、标本处理、大体及组织学分型、临床分期及分子病理检测等。分子检测含诊断、靶向治疗等标志物，NGS 可指导治疗，仍在探索中。

PD-1等多线治疗失败的晚期MSI-H胃癌，卡度尼利单抗+阿帕替尼四线治疗PFS超20个月

研究结果为未来临床试验提供了有价值的参考依据，为MSI-H胃癌的后线治疗策略提供了新视角，突显了双特异性抗体与抗血管治疗联合应用的潜力。

【专家述评】｜2024晚期胃癌诊疗指南更新对比与梳理：CSCO、NCCN和ESMO

本文基于不同指南内容展现出不同的视角与侧重，以丰富临床决策的维度，增强循证医学指南的临床适应性，进而指导临床实践。

GUT：空军军医大学季刚团队建立了一种用于检测早发型胃癌的新方案，具有更好的诊断性能

该研究报告了基于细胞外囊泡衍生lncRNA的液体活检信号对早期胃癌的早期检测的诊断效力。

2024年《NCCN胃癌临床实践指南》更新要点解读

本文将对指南中有关诊断、外科治疗、系统治疗、随访监测等方面进行重点解读，以期为临床实践提供指导和帮助。